IOA-289 is under clinical development by IOnctura and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how IOA-289’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
IOA-289 is under development for the treatment of solid tumors, idiopathic pulmonary fibrosis, and metastatic pancreatic cancer. The drug candidate acts by targeting autotaxin inhibitor. It was also under development for the treatment of inflammation. It is administered through oral route.
iOnctura is a biopharmaceutical company developing precision drugs targeting the tumor-stroma-immune interface for cancer indications and fibrosis. iOnctura is headquartered in Geneva, Switzerland.
For a complete picture of IOA-289’s drug-specific PTSR and LoA scores, buy the report here.